Medical Patent News

RSS

Spectrum Pharmaceuticals receives notice of a U.S. patent allowance for potential drug fo ADHD

Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."

21 Jul 2005

Webster University announces new M.A. in patent agency

Webster University's College of Arts & Sciences is offering a graduate degree program in Patent Agency. This 36-hour master of arts program, targeted towards working professionals in the technical and scientific fields, is the only known program of its kind nationally.

21 Jul 2005

Sigma-Aldrich licenses RNAi patent estate from Alnylam

Sigma-Aldrich Corporation and Alnylam Pharmaceuticals announced today that Alnylam has granted Sigma-Aldrich a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family.

19 Jul 2005

Chromos Molecular Systems issued four key patents

Chromos Molecular Systems has announced that it has further expanded the patent portfolio surrounding both its ACE System and REM Technology with the issuance of four key additional patents.

15 Jul 2005

Novadaq receives U.S. patent for intra-operative imaging procedure

Novadaq Technologies today announced that it has been granted a patent by the United States Patent and Trademark Office for the SPY(TM) Intra-operative Imaging System (SPY System).

13 Jul 2005

Stressgen granted U.S. patent providing coverage for the manufacture of HspE7

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted US Patent Number 6,900,035, covering methods of manufacturing HspE7, the Company's lead product candidate for human papillomavirus (HPV)- related diseases and cancer.

13 Jul 2005

Sirna Therapeutics granted new UK patents

Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).

12 Jul 2005

Map of gene control regions provides tool for understanding cells' different roles

In another step to decipher information in the human genome, scientists have discovered the location and sequence of over 10,000 DNA regions that function as genetic on-off switches, or "promoters" in human fibroblasts.

29 Jun 2005

Myriad Genetics issued new patent under license

Myriad Genetics has announced the issuance of Patent No. 6,911,466 entitled, "AB42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of compounds known as selective amyloid beta 42 lowering agents (SALAs) to lower levels of the toxic peptide.

29 Jun 2005

Cordis patents infringed by Boston Scientific Stents

Cordis Corporation today announced that a U.S. District Court jury in Wilmington, Delaware found that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal stents infringe Cordis' pioneering Palmaz patent for balloon expandable stents

21 Jun 2005

Brazil patent seizure threatens global trade and public health

With a number of other non-profit groups, ITSSD is calling attention to Brazil's threat to break U.S. patents on American AIDS drugs used as part of Brazil's government-funded treatment program.

19 Jun 2005

Neurocrine Biosciences issued new U.S. patent

Neurocrine Biosciences announced today the issuance of U.S. Patent No. 6,903,106 covering a novel polymorphic form (different crystal structure) of its proprietary compound indiplon for the treatment of insomnia.

16 Jun 2005

Immunomedics awarded U.S. and Australian patents

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

16 Jun 2005

GenoMed to be awarded new patent, for treating acute kidney failure without dialysis

GenoMed announced today that the US Patent Office has allowed claims and will be following up with an issued patent shortly on the Company's protocol to treat acute kidney failure with a drug rather than the dialysis machine.

14 Jun 2005

CalbaTech subsidiary files patent for stem cell delivery device

CalbaTech announced today that its wholly owned subsidiary, LifeStem has filed a U.S. Patent Application for its Stem Cell Delivery Device. The patent is for the Device and Methods for Treatment of Necrotic Tissue using Stem Cells.

14 Jun 2005

Chemokine Therapeutics granted new U.S patent

Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.

14 Jun 2005

Lorus Therapeutics receives patent allowance to protect novel anticancer drug

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.

9 Jun 2005